Health & Wellness
Squid Healthcare
The only FDA seeking product to address periocular post-procedure care
Dallas,
TX
Investment type:
Equity
(SAFE)
Target raise:
$200,000
- $1,070,000
Minimum investment:
$250
$250
End date:
Feb 23, 2022
Feb 23, 2022
ended
Share
Highlights
- ?? Huge market opportunity >$1B annually for an unmet medical & aesthetic need, growing at 15% CAGR
- ?? FDA 510(k) authorization (Rx & OTC) submitted after successfully completing testing requirements
- ?? Patent issued on utility, composition, design, and formulation(s)
- ?????????????? Co-founders are scientist with 15 yrs industry experience and oculoplastic surgeon
Our Story
We are a medical aesthetic company focused on inventing, developing, and bringing to market innovative solutions to address consumer and patient needs specifically related to periocular wellness.
Our Ambition
We plan to turn profitable by 2023 and cross $100M in global revenue by 2025 while ensuring a healthy operating margin.